1. Platsoucas CD, et al: Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha 7, an interferon similar to IFN-alpha J. Anticancer Re 9(4):849-858, 1989
2. Rook AH, Kuzel TM, Olsen EA: Cytokine therapy of cutaneous T-cell lymphoma: Interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 17(6):1435-1448, ix, 2003
3. Holman DM, Kalaaji AN: Cytokines in dermatology. J Drugs Dermatol 5(6):520-524, 2006
4. Motzer RJ et al: Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Onco 13(11):1799-1805, 2002
5. Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9(5):1089-1107, 1995
6. Richardson S et al: High clinical response rate with multimodality immunomodulatory therapy for Sezary syndrome. Clin Lymphoma Myeloma 7(3):226-232, 2006
7. Watanabe U et al: The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 89(3):399-403, 1994
8. Celik G et al: Sarcoidosis caused by interferon therapy. Respirology 10(4):535-540, 2005
9. Raanani P, Ben-Bassat I: Immune-mediated complications during interferon therapy in hematological patients. Acta Haemato 107(3):133-144, 2002
10. Gormley RH et al: Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. J Am Acad Dermatol 62(2):300-307, 2010
11. Sechler JM et al: Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci USA 85(13):4874-4878, 1988
12. Errante PR, Frazao JB, Condino-Neto A: The use of interferon-gamma therapy in chronic granulomatous disease. Recent Pat Antiinfect Drug Discov 3(3):225-230, 2008
13. Kaplan EH et al: Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82(3):208-212, 1990
14. Vowels BR et al: Aberrant cytokine production by Sezary syndrome patients: Cytokine secretion pattern resembles murine Th2 cells. J Invest Dermato 99(1):90-94, 1992
15. Kim EJ et al: Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115(4):798-812, 2005
16. Bolinger AM, Taeubel MA:Recombinant interferon gamma for treatment of chronic granulomatous disease and other disorders. Clin Pharm 11(10):834-850; quiz 892–834, 1992
17. Asadullah K, Sterry W, Trefzer U: Cytokine therapy in dermatology. Exp Dermatol 11(2):97-106, 2002
18. Atkins MB et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105-2116, 1999
19. Sznol M et al: Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma. Cancer Treat Rev 16(Suppl. A):29-38, 1989
20. Parkinson DR et al: Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 8(10):1650-1656, 1990
21. Jilaveanu LB, Aziz SA, Kluger HM: Chemotherapy and biologic therapies for melanoma: Do they work? Clin Dermatol 27(6):614-625, 2009
22. Goldbach-Mansky R et al: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355(6):581-592, 2006
23. Neven B et al: Long-term efficacy of the interleukin-1 receptor antagonist
anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
Arthritis Rheum 62(1):258-267, 2010
24. Szabolcs P et al: Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood 87(11):4520-4530, 1996
25. Kaplan G: Recent advances in cytokine therapy in leprosy. J Infect Dis 167 (Suppl. 1):S18–S22 1993
26. Braunstein S et al: GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo. J Invest Dermatol 103(4):601-604, 1994
27. Vaquerano JE et al: Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocyte-macrophage colony-stimulating factor. Arch Dermatol 135(10):1276-1277, 1999
28. Hoeller C et al: Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases. J Invest Dermatol 117(2):371-374, 2001
29. Spitler LE et al: Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 18(8):1614-1621, 2000
30. O'Day SJ et al: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 8(9):2775-2781, 2002
31. Spitler LE et al: Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF,
sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
J Immunother 32(6):632-637, 2009
32. Chaperot L et al: Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma. Leukemia. 14(9):1667-1677, 2000
33. Bouwhuis SA et al: Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sezary syndrome. Mayo Clin Proc 77(2):197-200, 2002
34. Wieman TJ, Smiell JM, Su Y: Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (
becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Diabetes Care 21(5):822-827, 1998
35. Steed DL: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 117(Suppl. 7):143S–149S; discussion 150S–151S, 2006
36. Smiell JM: Clinical safety of
becaplermin (rhPDGF-BB) gel.
Becaplermin Studies Group.
Am J Surg 176(Suppl. 2A):68S–73S, 1998
37. LaDuca JR, Gaspari AA: Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 19(4):617-635, 2001
38. Springer TA: Adhesion receptors of the immune system. Nature 346(6283):425-434, 1990
39. Gottlieb AB et al: Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (
infliximab) treatment of moderate to severe psoriasis vulgaris.
J Am Acad Dermatol 48(1):68-75, 2003
40. Hancock GE, Kaplan G, Cohn ZA: Keratinocyte growth regulation by the products of immune cells. J Exp Med 168(4):1395-1402, 1988
41. Gelfand JM et al: Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol 141(12):1537-1541, 2005
42. Ettehadi P: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96(1):146-151, 1994
43. Boyman O: Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 199(5):731-736, 2004
44. Bonifati C et al: Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients—Relationships with disease severity. Clin Exp Dermatol 19(5):383-387, 1994
45. Mussi A et al: Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 11(3):115-118, 1997
46. Sieper J, Van Den Brande J: Diverse effects of
infliximab and
etanercept on T lymphocytes.
Semin Arthritis Rheum. 34(5 Suppl. 1):23-27, 2005
47. Wallis RS, Ehlers S: Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of
etanercept and
infliximab.
Semin Arthritis Rheum34(5 Suppl. 1):34-38, 2005
48. Nestorov I: Clinical pharmacokinetics of TNF antagonists: How do they differ? Semin Arthritis Rheum 34(5 Suppl. 1):12-18, 2005
49. Wallis RS: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38(9):1261-1265, 2004
50. Alexis AF, Strober BE: Off-label dermatologic uses of anti-TNF-α therapies. J Cutan Med Surg 9(6):296-302, 2005
51. Grant A et al:
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial.
J Am Acad Dermatol 62(2):205-217, 2010
52. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60(10):800-805, 2005
53. Roux CH et al: Safety of anti-TNF-{alpha} therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford), 45(10):1294-1297 2006
54. Parke FA, Reveille JD: Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51(5):800-804, 2004
55. Zein NN:
Etanercept as an adjuvant to interferon and
ribavirin in treatment-naive patients with chronic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo-controlled study.
J Hepatol 42(3):315-322, 2005
56. Boetticher NC et al: A randomized, double-blinded, placebo-controlled multicenter trial of
etanercept in the treatment of alcoholic hepatitis.
Gastroenterology 135(6):1953-1960, 2008
57. Bongartz T et al: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275-2285, 2006
58. Strangfeld A et al: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7):737-744, 2009
59. Leombruno JP et al: The safety of antitumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68(7):1136-1145, 2009
60. Adams AE et al: Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol 51(4):660-662, 2004
61. Dommasch E, Gelfand JM: Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther 22(5):418-430, 2009
62. Bongartz T:
Etanercept therapy in rheumatoid arthritis and the risk of malignancies: A systematic review and individual patient data meta-analysis of randomised controlled trials.
Ann Rheum Dis 68(7):1177-1183, 2009
63. Mariette X et al: Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. Ann Rheum Dis 69(2):400-408, 2010
64. Gelfand JM et al: The Risk of lymphoma in patients with psoriasis. J Invest Dermatol 126(10):2194-2201, 2006
65. Ubriani R, Van Voorhees AS: Onset of psoriasis during treatment with TNF-{alpha} antagonists: A report of 3 cases. Arch Dermatol 143(2):270-272, 2007
66. Kary S et al: New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 65(3):405-407, 2006
67. Reich K et al:
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial.
Lancet 366(9494):1367-1374, 2005
68. Baert F et al:Influence of immunogenicity on the long-term efficacy of
infliximab in Crohn's disease.
N Engl J Med 348(7):601-608, 2003
69. Wagner CL et al: Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 112:37-53, 2003
70. Lipsky PE et al:
Infliximab and
methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
N Engl J Med 343(22):1594-1602, 2000
71. Kruger-Krasagakis S et al: Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br J Dermatol 154(3):460-466, 2006
72. Adams DR, Buckel T, Sceppa JA:
Infliximab associated new-onset psoriasis.
J Drugs Dermatol 5(2):178-179, 2006
73. Menter A et al:
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
J Am Acad Dermatol 58(1):106-115, 2010
74. Batchelor JM, Ingram JR, Williams H:
Adalimumab vs
methotrexate for the treatment of chronic plaque psoriasis.
Arch Dermatol 145(6):704-706; discussion 706, 2009
75. Lecluse LL et al: Extent and clinical consequences of antibody formation against
adalimumab in patients with plaque psoriasis.
Arch Dermatol 146(2):127-132, 2010
76. Torti DC, Feldman SR: Interleukin-12, interleukin-23, and psoriasis: Current prospects. J Am Acad Dermatol 57(6):1059-1068, 2007
77. Papp KA et al: Efficacy and safety of
ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Lancet 371(9625):1675-1684, 2008
78. Griffiths CE et al: Comparison of
ustekinumab and
etanercept for moderate-to-severe psoriasis.
N Engl J Med 362(2):118-128, 2010
79. Novelli F, Casanova JL: The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev. 15(5):367-377, 2004
80. MacLennan C et al: Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J Infect Dis 190(10):1755-1757, 2004
81. Van de Vosse E et al: Human genetics of intracellular infectious diseases: Molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis 4(12):739-749, 2004
82. Dorner T, Burmester GR: The role of B cells in rheumatoid arthritis: Mechanisms and therapeutic targets. Curr Opin Rheumatol 15(3):246-252, 2003
83. Edwards JC, Cambridge G: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40(2):205-211, 2001
84. Cerny T et al: Mechanism of action of
rituximab.
Anticancer Drug 13(Suppl. 2):S3–S10, 2002
86. Marcelin AG et al:
Rituximab therapy for HIV-associated Castleman disease.
Blood 102(8):2786-2788, 2003
87. Clifford KS, Demierre MF: Progression of classic Kaposi's sarcoma with
rituximab.
J Am Acad Dermatol 53(1):155-157, 2005
88. Schmidt E et al:
Rituximab in autoimmune bullous diseases: Mixed responses and adverse effects.
Br J Dermatol 156(2):352-356, 2007
89. Ahmed AR et al: Treatment of pemphigus vulgaris with
rituximab and intravenous immune globulin.
N Engl J Med 355(17):1772-1779, 2006
90. Kerl K et al: Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody
rituximab: report and follow-up of eight cases.
Br J Dermatol 155(6):1197-1200, 2006
91. Lafyatis R et al: B cell depletion with
rituximab in patients with diffuse cutaneous systemic sclerosis.
Arthritis Rheum 60(2):578-583, 2009
93. Ellis CN, Krueger GG: Treatment of ch ronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345(4):248-255 2001
94. Cooper JC et al: Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 33(3):666-675, 2003
95. Lebwohl M et al: An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139(6):719– 727, 2003
96. Fivenson DP, Mathes B: Treatment of generalized lichen planus with alefacept. Arch Dermatol 142(2):151-152, 2006
97. Heffernan MP et al: Alefacept for alopecia areata. Arch Dermatol 141(12):1513-1516, 2005
98. Strober BE et al: Alefacept for severe alopecia areata: A randomized, double-blind, placebo-controlled study. Arch Dermatol 145(11):1262-1266, 2009
99. Kraan MC et al: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 46(10):2776-2784, 2002
100. Mease PJ, Gladman DD, Keystone
EC:Alefacept in combination with
methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study.
Arthritis Rheum 54(5):1638-1645, 2006
101. Gribetz CH et al: An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 53(1):73-75, 2005
102. Menter A et al: The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 54(1):61-63, 2006
103. Goffe B et al: An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin The 27(12):1912-1921, 2005
104. Gottlieb AB et al: CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol 49(5):816-825, 2003
105. Leonardi CL et al:
Etanercept as monotherapy in patients with psoriasis.
N Engl J Med. 349(21):2014-2022, 20, 2003
106. Paller AS et al:
Etanercept treatment for children and adolescents with plaque psoriasis.
N Engl J Med. 358(3):241-251, 2008
107. Gottlieb AB et al: Etancercept can safely be withdrawn from patients with psoriasis and re-establishes disease control on retreatment. Presented at: Summer Academy 2004 of the American Academy of Dermatology New York, July 28–August 1, 2004, New York, Poster p. 89
108. Turk MJ et al: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200(6):771-782, 2004
109. Jones E et al: Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2:1, 2002
110. Attia P et al: Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28(6):582-592, 2005
111. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6(4):295-307, 2006
112. Olsen E et al:Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19(2):376-388, 2001
113. Talpur R et al: CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 126(3):575-583, 2006
114. Bagel J et al: Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial. J Am Acad Dermatol 38(6 Pt 1):938-944, 1998
115. Gottlieb AB et al: Use of interleukin-2 fusion protein, DAB389-IL-2, for the treatment of psoriasis. Dermatol Ther 5:48-63, 1998